Mathieu Bourgey

TL;DR: Findings argue for H3.3-mutation testing at diagnosis, which should be rapidly integrated into the clinical decision-making algorithm, particularly in atypical DIPG, while patients wild-type for H2.3 show improved survival.

TL;DR: This work integrated whole-genome sequencing with methylation, expression and copy number profiling, discovering that DIPGs comprise three molecularly distinct subgroups (H3-K27M, silent and MYCN) and uncovering a new recurrent activating mutation affecting the activin receptor gene ACVR1 in 20% of DIPG.

TL;DR: A conserved neural tri-lineage cancer hierarchy centered around glial progenitor-like cells is found, and this hierarchal map can be used to identify therapeutic targets specific to progenitors cancer stem cells.

TL;DR: It is discovered that differential methylation of a PDGFRB-associated enhancer confers specific sensitivity of group 2 ATRT cells to dasatinib and nilotinib, and it is suggested that these are promising therapies for this highly lethal ATRT subtype.

TL;DR: The results show that the processes underlyingccRCC tumorigenesis may vary in different populations and suggest that AA may be an important ccRCC carcinogen in Romania, a finding with major public health implications.